Does Mandatory Opioid Prescriber Education Go Far Enough? Congress Might Say No
Executive Summary
Congress and FDA already are sparring over the drug companies’ mandate to pay for the prescriber education included in the national prescription drug abuse plan.
You may also be interested in...
FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance
Manufacturers of long-acting/extended-release opioids must develop a blueprint for physician education in pain management with their products, but otherwise will be involved only at arms’ length in the doctor training portion of the Risk Evaluation and Mitigation Strategies.
FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance
Manufacturers of long-acting/extended-release opioids must develop a blueprint for physician education in pain management with their products, but otherwise will be involved only at arms’ length in the doctor training portion of the Risk Evaluation and Mitigation Strategies.
Remoxy’s "Complete Response" Letter Has No Clear Culprit But Many Suspects
Legal and safety issues continue to swirl around Pfizer and Pain Therapeutics’ Remoxy as it deals with the product’s second “complete response” letter in less than three years.